Phase II multicentre, randomised, double-blind, placebo and active-controlled, dose-ranging, parallel group study of Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769 in Combination With Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-Based Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2017
At a glance
- Drugs Aprepitant; Casopitant; Dexamethasone; Ondansetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 24 Mar 2009 Additional location China reported by ClinicalTrials.gov.
- 19 Dec 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History